Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines

Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to several clinical trials evaluating MEK inhibitors (MEKi). As LGSC cell lines and xenografts have been difficult to establish, little is know...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Cancer Res
Asıl Yazarlar: Fernández, Marta Llauradó, DiMattia, Gabriel E, Dawson, Amy, Bamford, Sylvia, Anderson, Shawn, Hennessy, Bryan T, Anglesio, Michael S, Shepherd, Trevor G, Salamanca, Clara, Hoenisch, Josh, Tinker, Anna, Huntsman, David G, Carey, Mark S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: e-Century Publishing Corporation 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5088288/
https://ncbi.nlm.nih.gov/pubmed/27822414
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller